Drug Trial for Preterm Infants (for babies less than 24 hours old)
Protocol: STUDY00001881
Full Title
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
Description

Technical Description

(CSR #170975144639) Preterm infants administered weekly Darbe starting within 36 hours of birth and continuing to 35 weeks gestational age will have improved neurocognitive outcome at 22-26 months (with deaths assigned the lowest possible score of 54), compared to placebo recipients.
Compensation: No
Eligibility
Children who are newborns (only infants who are 23-28 weeks at birth and who are less than 24 hours of age are eligible).
Age Group: Children
Principal Investigator: ANNE MARIE LYNDAKER
ClinicalTrials.gov: Open Study
Contact(s)
Emily Li
esli@buffalo.edu
Want to Learn More?
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.